284 related articles for article (PubMed ID: 10421545)
1. The dependence of prostate postimplant dosimetric quality on CT volume determination.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1111-7. PubMed ID: 10421545
[TBL] [Abstract][Full Text] [Related]
2. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
3. Is intraoperative nomogram-based overplanning of prostate implants necessary?
D'Souza WD; Lee HK; Palmer MB; Smith LG; Pollack A
Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):462-7. PubMed ID: 12738321
[TBL] [Abstract][Full Text] [Related]
4. Potential role of various dosimetric quality indicators in prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):717-24. PubMed ID: 10348304
[TBL] [Abstract][Full Text] [Related]
5. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
6. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy.
Mashouf S; Safigholi H; Merino T; Soliman A; Ravi A; Morton G; Song WY
Brachytherapy; 2016; 15(6):774-779. PubMed ID: 27720310
[TBL] [Abstract][Full Text] [Related]
8. The effect of interobserver variability on transrectal ultrasonography-based postimplant dosimetry.
Xue J; Waterman F; Handler J; Gressen E
Brachytherapy; 2006; 5(3):174-82. PubMed ID: 16864069
[TBL] [Abstract][Full Text] [Related]
9. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
Al-Qaisieh B; Witteveen T; Carey B; Henry A; Bottomley D; Smith J; Franks K; Bownes P
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):626-30. PubMed ID: 19540077
[TBL] [Abstract][Full Text] [Related]
10. Postimplantation dosimetric analysis of permanent transperineal prostate implantation: improved dose distributions with an intraoperative computer-optimized conformal planning technique.
Zelefsky MJ; Yamada Y; Cohen G; Venkatraman ES; Fung AY; Furhang E; Silvern D; Zaider M
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):601-8. PubMed ID: 10974481
[TBL] [Abstract][Full Text] [Related]
11. [Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy].
Herein A; Ágoston P; Szabó Z; Jorgo K; Markgruber B; Pesznyák C; Polgár C; Major T
Magy Onkol; 2015 Jun; 59(2):148-53. PubMed ID: 26035163
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging-defined treatment margins in iodine-125 prostate brachytherapy.
Crook J; Patil N; Ma C; McLean M; Borg J
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1079-84. PubMed ID: 19879700
[TBL] [Abstract][Full Text] [Related]
13. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
14. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer.
Morris WJ; Keyes M; Palma D; McKenzie M; Spadinger I; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Lapointe V; Berthelet E; Pai H; Harrison R; Kwa W; Bucci J; Racz V; Woods R
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1432-8. PubMed ID: 19036530
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
[TBL] [Abstract][Full Text] [Related]
17. Live implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy.
Roshan D; Joyce K; Woulfe P; Gorakati PR; Stock R; Sullivan FJ
Brachytherapy; 2021; 20(4):873-882. PubMed ID: 33840634
[TBL] [Abstract][Full Text] [Related]
18. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy.
Prestidge BR; Bice WS; Kiefer EJ; Prete JJ
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1111-5. PubMed ID: 9539566
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric comparison between model 9011 and 6711 sources in prostate implants.
Zhang H; Beyer D
Med Dosim; 2013; 38(2):199-203. PubMed ID: 23510715
[TBL] [Abstract][Full Text] [Related]
20. A detailed examination of the difference between planned and treated margins in 125I permanent prostate brachytherapy.
Patel AB; Waterman FM; Dicker AP
Brachytherapy; 2003; 2(4):223-8. PubMed ID: 15062130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]